These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 29055473)

  • 1. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis.
    Diaz-Cruz C; Chua AS; Malik MT; Kaplan T; Glanz BI; Egorova S; Guttmann CRG; Bakshi R; Weiner HL; Healy BC; Chitnis T
    Mult Scler Relat Disord; 2017 Oct; 17():47-53. PubMed ID: 29055473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis.
    Foster M; Zivadinov R; Weinstock-Guttman B; Tamaño-Blanco M; Badgett D; Carl E; Ramanathan M
    J Neuroimmunol; 2012 Feb; 243(1-2):61-8. PubMed ID: 22261546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
    J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.
    Tauhid S; Chu R; Sasane R; Glanz BI; Neema M; Miller JR; Kim G; Signorovitch JE; Healy BC; Chitnis T; Weiner HL; Bakshi R
    J Neurol; 2015 Nov; 262(11):2425-32. PubMed ID: 26205635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study.
    Bakshi R; Healy BC; Dupuy SL; Kirkish G; Khalid F; Gundel T; Asteggiano C; Yousuf F; Alexander A; Hauser SL; Weiner HL; Henry RG;
    J Neuroimaging; 2020 Mar; 30(2):212-218. PubMed ID: 31994814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis.
    Healy BC; Buckle GJ; Ali EN; Egorova S; Khalid F; Tauhid S; Glanz BI; Chitnis T; Guttmann CRG; Weiner HL; Bakshi R
    J Neuroimaging; 2017 Sep; 27(5):481-485. PubMed ID: 28261936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and diagnostic features of patients with familial multiple sclerosis.
    Andrijauskis D; Balnyte R; Keturkaite I; Vaitkus A
    Med Hypotheses; 2019 Oct; 131():109310. PubMed ID: 31443766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Food allergies are associated with increased disease activity in multiple sclerosis.
    Fakih R; Diaz-Cruz C; Chua AS; Gonzalez C; Healy BC; Sattarnezhad N; Glanz BI; Weiner HL; Chitnis T
    J Neurol Neurosurg Psychiatry; 2019 Jun; 90(6):629-635. PubMed ID: 30563943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; De Keyser J
    Eur J Neurol; 2012 Apr; 19(4):616-24. PubMed ID: 22117611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Zivadinov R; Qu J; Cookfair D; Duan X; Bang E; Bergsland N; Hussein S; Cherneva M; Willis L; Heininen-Brown M; Ramanathan M
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):189-95. PubMed ID: 21047880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
    Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
    Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
    Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    Kim G; Tauhid S; Dupuy SL; Tummala S; Khalid F; Healy BC; Bakshi R
    J Neurol; 2016 Mar; 263(3):531-8. PubMed ID: 26754005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between MRI parameters and the MS severity scale: a 12 year follow-up study.
    Minneboo A; Uitdehaag BM; Jongen P; Vrenken H; Knol Dl; van Walderveen MA; Polman CH; Castelijns JA; Barkhof F
    Mult Scler; 2009 May; 15(5):632-7. PubMed ID: 19389751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting short-term disability in multiple sclerosis.
    Gauthier SA; Mandel M; Guttmann CR; Glanz BI; Khoury SJ; Betensky RA; Weiner HL
    Neurology; 2007 Jun; 68(24):2059-65. PubMed ID: 17562826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice.
    Baldassari LE; Nakamura K; Moss BP; Macaron G; Li H; Weber M; Jones SE; Rao SM; Miller D; Conway DS; Bermel RA; Cohen JA; Ontaneda D; McGinley MP
    Mult Scler Relat Disord; 2020 Feb; 38():101525. PubMed ID: 31759186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.